Abstract
Malignant melanoma is a major contributor of skin cancer related mortality with increasing incidence and resistance to therapy. Advanced melanoma has a poor prognosis with a median overall survival of 8-10 months and a 5-year survival rate of 10%. A better understanding of melanogenesis and the tumor microenvironment has led to the development of several new therapies for metastatic melanoma. This review will provide a comprehensive overview of FDA approved novel systemic therapies for advanced melanoma and of other classes of molecules under clinical investigation. This paper will then look at the key signaling pathways these therapies target and briefly discuss the utility of biomarkers in guiding targeted therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
